1 / 6

PPAR  activation & lipid metabolism

PPAR  activation & lipid metabolism. Diabetic dyslipidaemia. Lipid profiles and hyperinsulinaemia in newly diagnosed type 2 diabetic patients. Niskanen L et al. Diabetes Care 1998;21:1861-9. Effects of pioglitazone vs gliclazide addition to metformin on dyslipidaemia.

ziazan
Download Presentation

PPAR  activation & lipid metabolism

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PPAR activation & lipid metabolism

  2. Diabetic dyslipidaemia Lipid profiles and hyperinsulinaemia in newly diagnosed type 2 diabetic patients Niskanen L et al. Diabetes Care 1998;21:1861-9

  3. Effects of pioglitazonevsgliclazide addition to metformin on dyslipidaemia HDLcholesterol LDLcholesterol TC / HDL ratio Triglycerides 30.00 22 20.00 10.00 7 % change from baseline after 2 yrs 2 0.00 -6 p<0.001 -10.00 -7 -10 p<0.001 -17 -20.00 -23 Pioglitazone + Metformin p<0.001 -30.00 Gliclazide + Metformin p<0.001 Betteridge DJ, Verges B. Diabetologia 2005; 48: 2477-81

  4. * * † * Change from baseline to endpoint (%) after 24 weeks * † * † * 2.9 2.7 1.0 1.0 4.0 4.0 Triglycerides HDL-C Non-HDL-C 2.3 2.8 1.15 1.08 4.1 4.6 Mean baseline mmol/L Mean endpoint mmol/L Changes in dyslipidaemic profile with TZDs *p<0.05 vs baseline; † p<0.001 between treatment groups Goldberg RB et al. Diabetes Care 2005; 28: 1547–1554 Goldberg RB et al. Circulation 2005; 111: 1727–1728

  5. Sulfonylurea + TZD or metformin:Comparison of lipid and renal effects N = 639 with poorly controlled DM2 † Change after 52 wks(%) † ‡ † * Metformin 850–2550 mg + sulfonylurea Pioglitazone 15–45 mg + sulfonylurea *P = 0.008, †P < 0.001, ‡P = NS Hanefeld M et al. Diabetes Care. 2004;27:141-7.

  6. TZDs and metformin reduce risk of MI Case-control study of insulin-sensitizing therapy and first MI in patients with type 2 diabetes n Insulin-sensitizing drugs Sulfonylureamonotherapy P Patients Controls Monotherapy Metformin 38 87 0.01 TZD 7 19 0.03 Combination therapy TZD + sulfonylurea 7 18 0.04 Metformin + sulfonylurea 40 62 0.19 0 0.2 0.4 0.6 0.8 1.0 1.2 Odds ratio for MI (95% CI)* *Adjusted for age, sex, BMI, ACE inhibitor use, history of hypertension or hypercholesterolemia Sauer WH et al. Am J Cardiol. 2006; 97:651-4.

More Related